Peptide Therapeutics Market to Witness 5.94% CAGR by 2031
Westford, USA, Sept. 27, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that Peptide Therapeutics Market will attain the value of USD 68.4 Billion by 2031, with a CAGR of 5.94% during…
Producers Online
Westford, USA, Sept. 27, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that Peptide Therapeutics Market will attain the value of USD 68.4 Billion by 2031, with a CAGR of 5.94% during…
Westford, USA, Sept. 27, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Global Drug Screening Market will reach a value of USD 35.18 Billion by 2031, with a CAGR of…
Westford, USA, Sept. 27, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Global Eyewear Market will reach a value of USD 357.1 Billion by 2031, with a CAGR of 8.4%…
TORONTO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Fredonia Mining Inc. (TSXV: FRED) (the “Company” or “Fredonia”) is pleased to announce the closing of its previously announced non-brokered private placement, consisting…
Rapport Financier semestriel 2024 La Caisse Régionale de Crédit Agricole Mutuel Brie Picardie compte au 30 juin 2024 :• 206 agences de Proximité• 1 agence Gestion de la Relation à…
PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.KEY INFORMATION (a)Full name of discloser:Invesco Ltd. (b)Owner or controller…
Delhi, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights: Bispecific Antibodies Development Proprietary Platforms Insight: > 30…
LAS VEGAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Tritent International Corp. ("Tritent"), a US public company (US OTC: TICJ), and Burst Technologies, Inc. ("Burst Technologies"), a Delaware corporation, are pleased…
WALNUT, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Armlogi Holding Corp. (“Armlogi” or the “Company”) (Nasdaq: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of…
The intended selling valuation represents an increase of 47% from the valuation at the time of SciSparc’s initial investment in MitoCareX Bio TEL AVIV, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE)…